NASDAQ:CTMX - CytomX Therapeutics Stock Price, Price Target & More

$26.08 -0.49 (-1.84 %)
(As of 04/25/2018 01:13 AM ET)
Previous Close$26.57
Today's Range$25.62 - $26.71
52-Week Range$13.00 - $35.00
Volume328,136 shs
Average Volume368,221 shs
Market Capitalization$1.04 billion
P/E Ratio-22.54
Dividend YieldN/A
Beta0.91

About CytomX Therapeutics (NASDAQ:CTMX)

CytomX Therapeutics logoCytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Bristol-Myers Squibb Company, ImmunoGen, Inc., MD Anderson, and Pfizer Inc. to develop Probody therapeutics. It also has a strategic collaboration with Amgen, Inc. to develop T cell-bispecific probody therapeutic targeting epidermal growth factor receptor-CD3. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Receive CTMX News and Ratings via Email

Sign-up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CTMX
CUSIPN/A
Phone650-515-3185

Debt

Debt-to-Equity RatioN/A
Current Ratio6.36%
Quick Ratio6.36%

Price-To-Earnings

Trailing P/E Ratio-22.54
Forward P/E Ratio-18.11
P/E GrowthN/A

Sales & Book Value

Annual Sales$71.62 million
Price / Sales14.06
Cash FlowN/A
Price / CashN/A
Book Value$1.82 per share
Price / Book14.33

Profitability

EPS (Most Recent Fiscal Year)($1.16)
Net Income$-43,090,000.00
Net Margins-60.17%
Return on Equity-71.42%
Return on Assets-13.12%

Miscellaneous

Employees93
Outstanding Shares38,610,000

How to Become a New Pot Stock Millionaire

CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions

What is CytomX Therapeutics' stock symbol?

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics (NASDAQ:CTMX) released its quarterly earnings results on Wednesday, March, 7th. The biotechnology company reported $0.02 EPS for the quarter, topping analysts' consensus estimates of ($0.43) by $0.45. The biotechnology company had revenue of $27.07 million for the quarter, compared to the consensus estimate of $10.70 million. CytomX Therapeutics had a negative net margin of 60.17% and a negative return on equity of 71.42%. View CytomX Therapeutics' Earnings History.

When is CytomX Therapeutics' next earnings date?

CytomX Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, May, 3rd 2018. View Earnings Estimates for CytomX Therapeutics.

What price target have analysts set for CTMX?

10 equities research analysts have issued 1-year price objectives for CytomX Therapeutics' shares. Their predictions range from $37.00 to $44.00. On average, they anticipate CytomX Therapeutics' stock price to reach $40.1667 in the next year. View Analyst Ratings for CytomX Therapeutics.

What are Wall Street analysts saying about CytomX Therapeutics stock?

Here are some recent quotes from research analysts about CytomX Therapeutics stock:
  • 1. According to Zacks Investment Research, "CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. " (3/12/2018)
  • 2. Cann analysts commented, "Loss per share was $0.69, compared to our estimate of $0.56. This was the result of higher than expected R&D expense of $28.1 million compared to our estimate of $15.2 million, which resulted from a $10 million payment to UCSB for a sublicense payment. This was partially offset by higher than estimated revenue of $8.8 million compared to our estimated $1.0 million." (8/8/2017)
  • 3. Cowen Inc analysts commented, "CTMX announced that the first patient in CX-2009’s (CD166 PDC) Phase I trial has." (6/28/2017)
  • 4. HC Wainwright analysts commented, "Before the market opened on May 5, TG reported 1Q17 results. The company recently reported preliminary data from its ongoing Phase II study of TG-1101 in patients with relapsing forms of multiple sclerosis. Preliminary results indicated that TG-1101 was well tolerated with no Grade III/IV adverse events (AEs) observed and the most commonly reported AE being infusion-related reactions, with median time on study of five months. All patients achieved the primary endpoint of greater than 95% B-cell depletion by four weeks. The median B-cell depletion at week four was reported to be 99% after two infusions with a cumulative dose of 600 mg, which compares favorably to other anti-CD20 monoclonal antibodies (mAbs). Management indicated that additional data from the ongoing Phase II study will be reported later this year and that the company is on track to initiate a Phase III trial in MS in 2H17." (5/8/2017)

Who are some of CytomX Therapeutics' key competitors?

Who are CytomX Therapeutics' key executives?

CytomX Therapeutics' management team includes the folowing people:
  • Dr. Sean A. McCarthy, Pres, CEO & Director (Age 51)
  • Mr. Frederick W. Gluck, Co-Founder & Director (Age 83)
  • Dr. W. Michael Kavanaugh M.D., Chief Scientific Officer and Head of Research & Non-Clinical Devel. (Age 62)
  • Dr. Rachel Wallach Humphrey M.D., Ph.D., Chief Medical Officer (Age 57)
  • Prof. Patrick S. Daugherty Ph.D., Founder and Member of Scientific Advisory Board

Has CytomX Therapeutics been receiving favorable news coverage?

News articles about CTMX stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. CytomX Therapeutics earned a media sentiment score of 0.05 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 45.95 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of CytomX Therapeutics?

Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CytomX Therapeutics' stock price today?

One share of CTMX stock can currently be purchased for approximately $26.08.

How big of a company is CytomX Therapeutics?

CytomX Therapeutics has a market capitalization of $1.04 billion and generates $71.62 million in revenue each year. The biotechnology company earns $-43,090,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. CytomX Therapeutics employs 93 workers across the globe.

How can I contact CytomX Therapeutics?

CytomX Therapeutics' mailing address is 151 OYSTER POINT BOULEVARD SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected]


MarketBeat Community Rating for CytomX Therapeutics (CTMX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  182 (Vote Outperform)
Underperform Votes:  132 (Vote Underperform)
Total Votes:  314
MarketBeat's community ratings are surveys of what our community members think about CytomX Therapeutics and other stocks. Vote "Outperform" if you believe CTMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTMX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

CytomX Therapeutics (NASDAQ:CTMX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
10 Wall Street analysts have issued ratings and price targets for CytomX Therapeutics in the last 12 months. Their average twelve-month price target is $40.1667, suggesting that the stock has a possible upside of 54.01%. The high price target for CTMX is $44.00 and the low price target for CTMX is $37.00. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.802.642.60
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $40.1667$37.8571$33.8750$33.00
Price Target Upside: 54.01% upside11.34% upside48.12% upside64.67% upside

CytomX Therapeutics (NASDAQ:CTMX) Consensus Price Target History

Price Target History for CytomX Therapeutics (NASDAQ:CTMX)

CytomX Therapeutics (NASDAQ:CTMX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/17/2018Cantor FitzgeraldSet Price TargetBuy$40.00LowView Rating Details
3/8/2018Jefferies GroupBoost Price TargetBuy$40.00HighView Rating Details
3/8/2018Bank of AmericaBoost Price TargetBuy -> Buy$34.00 -> $40.00HighView Rating Details
1/5/2018CitigroupInitiated CoverageBuy -> Buy$40.00HighView Rating Details
10/5/2017CowenReiterated RatingOutperformN/AView Rating Details
10/4/2017OppenheimerReiterated RatingHoldHighView Rating Details
10/4/2017NomuraBoost Price TargetBuy$44.00HighView Rating Details
10/4/2017WedbushSet Price TargetBuy$26.00 -> $37.00HighView Rating Details
8/8/2017CannReiterated RatingHoldHighView Rating Details
5/8/2017HC WainwrightReiterated RatingBuyLowView Rating Details
3/20/2017InstinetBoost Price TargetSell$21.00 -> $32.00MediumView Rating Details
(Data available from 4/25/2016 forward)

Earnings

CytomX Therapeutics (NASDAQ:CTMX) Earnings History and Estimates Chart

Earnings by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

CytomX Therapeutics (NASDAQ:CTMX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.85)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.27)($0.01)($0.14)
Q2 20182($0.31)($0.08)($0.20)
Q3 20182($0.34)($0.14)($0.24)
Q4 20182($0.36)($0.18)($0.27)

CytomX Therapeutics (NASDAQ CTMX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2018($0.23)N/AView Earnings Details
3/7/2018Q4 2017($0.43)$0.02$10.70 million$27.07 millionViewN/AView Earnings Details
11/7/2017Q3 2017($0.14)($0.28)$16.60 million$24.14 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.39)($0.69)$4.95 million$8.75 millionViewListenView Earnings Details
5/5/2017Q1 2017($0.55)($0.23)$2.10 million$11.65 millionViewN/AView Earnings Details
3/2/2017Q4 2016($0.45)($0.39)$6.27 millionViewN/AView Earnings Details
11/3/2016Q3($0.35)($0.40)$3.20 million$3.45 millionViewN/AView Earnings Details
8/3/2016Q2($0.41)($0.39)$2.10 million$3.09 millionViewN/AView Earnings Details
5/6/2016Q1 2016($0.26)($0.44)$6.00 million$2.22 millionViewN/AView Earnings Details
3/7/2016Q4 2015($0.34)($0.39)$1.75 million$1.99 millionViewN/AView Earnings Details
11/23/2015Q3 2015($0.25)($14.26)$1.75 million$1.94 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

CytomX Therapeutics (NASDAQ:CTMX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

CytomX Therapeutics (NASDAQ CTMX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.00%
Institutional Ownership Percentage: 78.36%
Insider Trading History for CytomX Therapeutics (NASDAQ:CTMX)
Institutional Ownership by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

CytomX Therapeutics (NASDAQ CTMX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/2/2018Debanjan RayCFOSell3,000$28.12$84,360.007,741View SEC Filing  
3/26/2018Frederick W GluckDirectorSell5,000$31.93$159,650.00View SEC Filing  
3/2/2018Debanjan RayCFOSell33,000$29.99$989,670.00View SEC Filing  
3/2/2018Frederick W GluckDirectorSell16,181$30.00$485,430.00View SEC Filing  
3/2/2018Rachel HumphreyInsiderSell16,160$30.00$484,800.0046,394View SEC Filing  
2/28/2018Frederick W GluckDirectorSell3,819$30.00$114,570.00View SEC Filing  
2/28/2018Rachel HumphreyInsiderSell23,840$30.00$715,200.0054,074View SEC Filing  
2/1/2018Debanjan RayCFOSell2,548$26.69$68,006.124,741View SEC Filing  
1/5/2018Frederick W GluckDirectorSell10,000$25.01$250,100.00View SEC Filing  
1/5/2018Sean A MccarthyInsiderSell6,526$25.01$163,215.2611,169View SEC Filing  
1/2/2018Debanjan RayCFOSell2,500$21.11$52,775.00View SEC Filing  
1/2/2018Sean A MccarthyInsiderSell13,052$21.04$274,614.0817,695View SEC Filing  
12/26/2017Frederick W GluckDirectorSell5,000$22.29$111,450.00View SEC Filing  
12/1/2017Debanjan RayCFOSell2,500$20.58$51,450.00View SEC Filing  
12/1/2017Sean A MccarthyInsiderSell14,340$20.60$295,404.00View SEC Filing  
11/1/2017Debanjan RayCFOSell2,500$20.00$50,000.0012,126View SEC Filing  
11/1/2017Sean A MccarthyCEOSell14,342$19.86$284,832.1218,587View SEC Filing  
10/4/2017Frederick W GluckDirectorSell10,000$24.27$242,700.00View SEC Filing  
10/4/2017Robert I TepperMajor ShareholderSell24,777$24.34$603,072.18View SEC Filing  
10/4/2017Sean A MccarthyCEOSell19,120$24.13$461,365.6023,365View SEC Filing  
10/4/2017William Michael KavanaughInsiderSell48,368$24.34$1,177,277.12View SEC Filing  
10/2/2017Debanjan RayCFOSell2,500$18.10$45,250.00View SEC Filing  
10/2/2017Sean A MccarthyInsiderSell9,562$18.57$177,566.34View SEC Filing  
9/26/2017Frederick W GluckDirectorSell5,000$17.30$86,500.00View SEC Filing  
9/19/2017Robert I TepperMajor ShareholderSell20,000$18.00$360,000.0054,293View SEC Filing  
9/1/2017Debanjan RayCFOSell2,500$17.17$42,925.0017,126View SEC Filing  
9/1/2017Sean A MccarthyInsiderSell9,930$17.32$171,987.6014,175View SEC Filing  
8/31/2017Sean A MccarthyInsiderSell18,756$17.50$328,230.0023,001View SEC Filing  
8/9/2017Debanjan RayCFOSell2,500$15.00$37,500.0019,626View SEC Filing  
8/9/2017Sean A MccarthyInsiderSell4,781$15.00$71,715.009,026View SEC Filing  
7/3/2017Debanjan RayCFOSell2,500$15.47$38,675.0022,126View SEC Filing  
7/3/2017Sean A MccarthyInsiderSell4,781$15.52$74,201.129,026View SEC Filing  
6/29/2017Robert I TepperMajor ShareholderSell15,000$16.00$240,000.0044,777View SEC Filing  
6/26/2017Frederick W GluckDirectorSell5,000$14.61$73,050.00View SEC Filing  
6/26/2017Sean A MccarthyInsiderSell4,481$15.00$67,215.008,726View SEC Filing  
6/5/2017Sean A MccarthyInsiderSell300$15.00$4,500.004,545View SEC Filing  
5/1/2017Sean A MccarthyInsiderSell4,781$15.70$75,061.706,760View SEC Filing  
4/12/2017Kevin P StarrMajor ShareholderSell28,357$16.36$463,920.5231,419View SEC Filing  
4/4/2017Sean A MccarthyInsiderSell9,562$17.22$164,657.646,760View SEC Filing  
3/27/2017Rock Ventures Lp ThirdMajor ShareholderSell1,650,000$17.39$28,693,500.00View SEC Filing  
3/20/2017Robert C Goeltz IICFOSell21,517$19.81$426,251.7731,306View SEC Filing  
3/20/2017Sean A MccarthyInsiderSell14,343$19.60$281,122.8016,322View SEC Filing  
3/3/2017Sean A MccarthyInsiderSell14,343$15.00$215,145.0016,322View SEC Filing  
11/28/2016Ix L.P. CanaanDirectorSell38,459$11.56$444,586.04View SEC Filing  
11/22/2016Ix L.P. CanaanDirectorSell42,550$11.71$498,260.50View SEC Filing  
11/21/2016Ix L.P. CanaanDirectorSell45,324$11.61$526,211.64View SEC Filing  
11/16/2016Ix L.P. CanaanDirectorSell51,581$11.50$593,181.50View SEC Filing  
11/15/2016Timothy M ShannonDirectorSell33,064$11.48$379,574.72268View SEC Filing  
11/14/2016Ix L.P. CanaanDirectorSell86,270$11.16$962,773.20View SEC Filing  
11/9/2016Ix L.P. CanaanDirectorSell13,730$11.03$151,441.90View SEC Filing  
6/10/2016Timothy M ShannonDirectorSell48,427$10.07$487,659.89134View SEC Filing  
6/7/2016Ix L.P. CanaanDirectorSell111,498$10.01$1,116,094.98View SEC Filing  
6/3/2016Ix L.P. CanaanDirectorSell59,621$10.80$643,906.80View SEC Filing  
6/1/2016Ix L.P. CanaanDirectorSell22,463$10.75$241,477.25View SEC Filing  
5/27/2016Ix L.P. CanaanDirectorSell25,082$10.60$265,869.20View SEC Filing  
5/26/2016Timothy M ShannonDirectorSell51,343$10.34$530,886.62134View SEC Filing  
5/24/2016Ix L.P. CanaanDirectorSell13,253$10.09$133,722.77View SEC Filing  
5/20/2016Ix L.P. CanaanDirectorSell8,687$10.10$87,738.70View SEC Filing  
10/14/2015Cynthia J LaddVPBuy3,000$12.00$36,000.003,000View SEC Filing  
10/14/2015Frederick W GluckDirectorBuy15,000$12.00$180,000.00147,791View SEC Filing  
10/14/2015James E FlynnInsiderBuy625,000$12.00$7,500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

CytomX Therapeutics (NASDAQ CTMX) News Headlines

Source:
DateHeadline
CytomX Therapeutics (CTMX) Cut to Hold at BidaskClubCytomX Therapeutics (CTMX) Cut to Hold at BidaskClub
www.americanbankingnews.com - April 18 at 10:05 AM
BidaskClub Downgrades CytomX Therapeutics (CTMX) to SellBidaskClub Downgrades CytomX Therapeutics (CTMX) to Sell
www.americanbankingnews.com - April 16 at 8:40 PM
CytomX Therapeutics (CTMX) Expected to Post Quarterly Sales of $19.77 MillionCytomX Therapeutics (CTMX) Expected to Post Quarterly Sales of $19.77 Million
www.americanbankingnews.com - April 15 at 2:14 AM
Zacks: Analysts Anticipate CytomX Therapeutics Inc (CTMX) to Announce -$0.30 Earnings Per ShareZacks: Analysts Anticipate CytomX Therapeutics Inc (CTMX) to Announce -$0.30 Earnings Per Share
www.americanbankingnews.com - April 13 at 9:19 PM
CytomX Therapeutics Inc (CTMX) Given Consensus Rating of "Buy" by AnalystsCytomX Therapeutics Inc (CTMX) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - April 12 at 5:43 PM
CytomX Therapeutics (CTMX) Upgraded to "Hold" at BidaskClubCytomX Therapeutics (CTMX) Upgraded to "Hold" at BidaskClub
www.americanbankingnews.com - April 11 at 10:10 PM
Insider Selling: CytomX Therapeutics Inc (CTMX) CFO Sells 3,000 Shares of StockInsider Selling: CytomX Therapeutics Inc (CTMX) CFO Sells 3,000 Shares of Stock
www.americanbankingnews.com - April 4 at 4:16 PM
CytomX Therapeutics (CTMX) Lifted to Hold at ValuEngineCytomX Therapeutics (CTMX) Lifted to Hold at ValuEngine
www.americanbankingnews.com - April 3 at 5:16 PM
CytomX Therapeutics (CTMX) Lowered to "Buy" at BidaskClubCytomX Therapeutics (CTMX) Lowered to "Buy" at BidaskClub
www.americanbankingnews.com - March 30 at 1:06 PM
$19.77 Million in Sales Expected for CytomX Therapeutics Inc (CTMX) This Quarter$19.77 Million in Sales Expected for CytomX Therapeutics Inc (CTMX) This Quarter
www.americanbankingnews.com - March 29 at 4:36 AM
Frederick W. Gluck Sells 5,000 Shares of CytomX Therapeutics Inc (CTMX) StockFrederick W. Gluck Sells 5,000 Shares of CytomX Therapeutics Inc (CTMX) Stock
www.americanbankingnews.com - March 27 at 10:35 PM
CytomX Therapeutics (CTMX) Upgraded at BidaskClubCytomX Therapeutics (CTMX) Upgraded at BidaskClub
www.americanbankingnews.com - March 25 at 9:30 AM
FY2018 Earnings Forecast for CytomX Therapeutics Inc Issued By Cantor Fitzgerald (CTMX)FY2018 Earnings Forecast for CytomX Therapeutics Inc Issued By Cantor Fitzgerald (CTMX)
www.americanbankingnews.com - March 23 at 10:54 AM
CytomX Therapeutics Inc Forecasted to Earn FY2019 Earnings of ($1.66) Per Share (CTMX)CytomX Therapeutics Inc Forecasted to Earn FY2019 Earnings of ($1.66) Per Share (CTMX)
www.americanbankingnews.com - March 22 at 3:16 PM
CytomX Therapeutics (CTMX) Given a $40.00 Price Target by Cantor Fitzgerald AnalystsCytomX Therapeutics (CTMX) Given a $40.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - March 18 at 1:46 PM
CytomX Therapeutics (CTMX) Downgraded by Zacks Investment Research to SellCytomX Therapeutics (CTMX) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - March 12 at 9:54 PM
FY2022 Earnings Estimate for CytomX Therapeutics Inc (CTMX) Issued By OppenheimerFY2022 Earnings Estimate for CytomX Therapeutics Inc (CTMX) Issued By Oppenheimer
www.americanbankingnews.com - March 12 at 10:02 AM
$22.15 Million in Sales Expected for CytomX Therapeutics Inc (CTMX) This Quarter$22.15 Million in Sales Expected for CytomX Therapeutics Inc (CTMX) This Quarter
www.americanbankingnews.com - March 12 at 4:09 AM
Wedbush Weighs in on CytomX Therapeutics Incs Q1 2018 Earnings (CTMX)Wedbush Weighs in on CytomX Therapeutics Inc's Q1 2018 Earnings (CTMX)
www.americanbankingnews.com - March 12 at 2:32 AM
CytomX Therapeutics (CTMX) PT Set at $40.00 by Cantor FitzgeraldCytomX Therapeutics (CTMX) PT Set at $40.00 by Cantor Fitzgerald
www.americanbankingnews.com - March 10 at 9:24 PM
Zacks: Analysts Anticipate CytomX Therapeutics Inc (CTMX) Will Post Earnings of -$0.22 Per ShareZacks: Analysts Anticipate CytomX Therapeutics Inc (CTMX) Will Post Earnings of -$0.22 Per Share
www.americanbankingnews.com - March 10 at 3:22 PM
CytomX Therapeutics Inc Expected to Post FY2022 Earnings of $3.32 Per Share (CTMX)CytomX Therapeutics Inc Expected to Post FY2022 Earnings of $3.32 Per Share (CTMX)
www.americanbankingnews.com - March 9 at 4:32 PM
Immuno-Oncology Sector Deals Dominate 2017 Life Sciences Deal of the Year AwardsImmuno-Oncology Sector Deals Dominate 2017 Life Sciences Deal of the Year Awards
www.bizjournals.com - March 8 at 6:51 PM
CytomX beats by $0.49, beats on revenueCytomX beats by $0.49, beats on revenue
seekingalpha.com - March 8 at 6:51 PM
CytomX Therapeutics (CTMX) PT Raised to $40.00 at Bank of AmericaCytomX Therapeutics (CTMX) PT Raised to $40.00 at Bank of America
www.americanbankingnews.com - March 8 at 6:41 PM
CytomX Therapeutics (CTMX) PT Raised to $40.00 at Jefferies GroupCytomX Therapeutics (CTMX) PT Raised to $40.00 at Jefferies Group
www.americanbankingnews.com - March 8 at 6:34 PM
Analyzing CytomX Therapeutics (CTMX) and Aclaris Therapeutics (ACRS)Analyzing CytomX Therapeutics (CTMX) and Aclaris Therapeutics (ACRS)
www.americanbankingnews.com - March 8 at 9:18 AM
CytomX Therapeutics (CTMX) CEO Sean McCarthy on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaCytomX Therapeutics' (CTMX) CEO Sean McCarthy on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 8 at 8:19 AM
CytomX Therapeutics beats Street 4Q forecastsCytomX Therapeutics beats Street 4Q forecasts
finance.yahoo.com - March 8 at 8:19 AM
CytomX Therapeutics, Inc. to Host Earnings CallCytomX Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - March 7 at 6:38 PM
What Does CytomX Therapeutics Inc’s (NASDAQ:CTMX) Past Performance Indicative Of Its Future?What Does CytomX Therapeutics Inc’s (NASDAQ:CTMX) Past Performance Indicative Of Its Future?
finance.yahoo.com - March 7 at 6:38 PM
CytomX Therapeutics Announces Full-Year 2017 Financial Results and Provides Operational UpdateCytomX Therapeutics Announces Full-Year 2017 Financial Results and Provides Operational Update
finance.yahoo.com - March 7 at 6:38 PM
Schroder Investment Management Group Acquires 52,348 Shares of CytomX Therapeutics Inc (CTMX)Schroder Investment Management Group Acquires 52,348 Shares of CytomX Therapeutics Inc (CTMX)
www.americanbankingnews.com - March 6 at 9:48 AM
CytomX Therapeutics Inc (CTMX) Insider Rachel Humphrey Sells 16,160 SharesCytomX Therapeutics Inc (CTMX) Insider Rachel Humphrey Sells 16,160 Shares
www.americanbankingnews.com - March 5 at 9:30 PM
Insider Selling: CytomX Therapeutics Inc (CTMX) Director Sells 16,181 Shares of StockInsider Selling: CytomX Therapeutics Inc (CTMX) Director Sells 16,181 Shares of Stock
www.americanbankingnews.com - March 5 at 9:30 PM
CytomX Therapeutics Inc (CTMX) CFO Debanjan Ray Sells 33,000 SharesCytomX Therapeutics Inc (CTMX) CFO Debanjan Ray Sells 33,000 Shares
www.americanbankingnews.com - March 5 at 6:40 PM
CytomX Therapeutics Inc (CTMX) Stake Raised by Bogle Investment Management L P DECytomX Therapeutics Inc (CTMX) Stake Raised by Bogle Investment Management L P DE
www.americanbankingnews.com - March 4 at 4:58 AM
CytomX Therapeutics Inc (CTMX) Director Sells $114,570.00 in StockCytomX Therapeutics Inc (CTMX) Director Sells $114,570.00 in Stock
www.americanbankingnews.com - March 2 at 12:14 PM
Rachel Humphrey Sells 23,840 Shares of CytomX Therapeutics Inc (CTMX) StockRachel Humphrey Sells 23,840 Shares of CytomX Therapeutics Inc (CTMX) Stock
www.americanbankingnews.com - March 2 at 12:14 PM
CytomX to Present at Upcoming Investor ConferencesCytomX to Present at Upcoming Investor Conferences
finance.yahoo.com - March 1 at 5:54 PM
CytomX Therapeutics (CTMX) Set to Announce Quarterly Earnings on WednesdayCytomX Therapeutics (CTMX) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 28 at 3:32 AM
CytomX Therapeutics to Announce Full-Year 2017 Financial Results and Host Operational Update Webcast ... - GlobeNewswire (press release)CytomX Therapeutics to Announce Full-Year 2017 Financial Results and Host Operational Update Webcast ... - GlobeNewswire (press release)
globenewswire.com - February 23 at 8:18 AM
$10.70 Million in Sales Expected for CytomX Therapeutics Inc (CTMX) This Quarter$10.70 Million in Sales Expected for CytomX Therapeutics Inc (CTMX) This Quarter
www.americanbankingnews.com - February 23 at 1:06 AM
CytomX Therapeutics to Announce Full-Year 2017 Financial Results and Host Operational Update Webcast Conference CallCytomX Therapeutics to Announce Full-Year 2017 Financial Results and Host Operational Update Webcast Conference Call
finance.yahoo.com - February 22 at 5:39 PM
CytomX Therapeutics Inc (CTMX) Receives Average Rating of "Buy" from BrokeragesCytomX Therapeutics Inc (CTMX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 21 at 7:30 PM
CytomX Therapeutics (CTMX) Lowered to "Sell" at Zacks Investment ResearchCytomX Therapeutics (CTMX) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - February 19 at 9:08 PM
Zacks Investment Research Lowers CytomX Therapeutics (CTMX) to SellZacks Investment Research Lowers CytomX Therapeutics (CTMX) to Sell
www.americanbankingnews.com - February 12 at 10:12 PM
CytomX Therapeutics (CTMX) Rating Lowered to Sell at Zacks Investment ResearchCytomX Therapeutics (CTMX) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - February 5 at 9:16 PM
 Analysts Anticipate CytomX Therapeutics Inc (CTMX) Will Post Earnings of -$0.39 Per Share Analysts Anticipate CytomX Therapeutics Inc (CTMX) Will Post Earnings of -$0.39 Per Share
www.americanbankingnews.com - February 4 at 9:06 PM
Insider Selling: CytomX Therapeutics Inc (CTMX) CFO Sells 2,548 Shares of StockInsider Selling: CytomX Therapeutics Inc (CTMX) CFO Sells 2,548 Shares of Stock
www.americanbankingnews.com - February 2 at 10:02 PM

SEC Filings

CytomX Therapeutics (NASDAQ:CTMX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

CytomX Therapeutics (NASDAQ:CTMX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

CytomX Therapeutics (NASDAQ CTMX) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.